MapLight’s schizophrenia program delivered a mixed Phase 2 readout tied to dosing frequency, sending the stock sharply lower after investors expected a clearer path to differentiation. The once-daily version of its M1/M4 agonist, ML-007C-MA, missed efficacy in the ZEPHYR trial, while a twice-daily regimen met the primary endpoint. In parallel commentary, MapLight CEO Chris Kroeger argued the broader dataset supports the therapy’s competitiveness and that investors focused too narrowly on the one dosing arm when assessing the full body of evidence. For the biotech market, the episode highlights how trial design and dosing strategy can swing mid-stage interpretations even when other arms show promise, and it raises the bar for clarity around which regimen is likely to advance.